Navigation Links
Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie
Date:9/5/2007

ding Canada and Mexico) and India.

In addition, Spectrum will receive 50 percent of any upfront and milestone payments, royalties and/or profits from sales of the product in Japan. Japanese rights for all potential oncology indications have recently been licensed to Nippon Kayaku, a key player in the Japanese oncology market.

Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent prostate cancer and other indications.

About Benign Prostatic Hypertrophy

Benign prostatic hypertrophy is a non-cancerous enlargement of the prostate frequently occurring in men over the age of 50. According to the National Institutes of Health, BPH affects more than 50% of men over the age of 60 and as many as 90% of men over the age of 70 and it is estimated that there are currently more than 28 million men suffering from BPH in the United States.

The IPSS (also known as AUA symptom index) is a standardized scoring system that evaluates the seven principal symptoms of BPH. The enlargement can result in the gradual squeezing of the urethra, resulting in increased frequency or difficulty in urinating. Treatment options for BPH include surgery and medications to reduce the amount of tissue and increase the flow of urine. Current treatment options have limited efficacy, leading to inadequate compliance. Medications currently available belong to two classes: alpha blockers (such as FLOMAX(R)[1], CARDURA(R)[2] and HYTRIN(R)[3]) which relax the muscles in the neck of the bladder and in the prostate, but have no direct effect on the prostate growth itself, and alpha reductase inhibitors (such as PROSCAR(R)[4] and AVODART(R)[5]), which can result in some reduction of the prostate size but have a very slow onset of action, and may be associated with impotence and decreased libido.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals acquires, develops and commercializes a diversified portfolio of oncology drug candidate
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 BioElectronics Corp. (PINKSHEETS: BIEL), the ... announced that CEO, Andrew J. Whelan ... Medical Advisory Committee, Orthopedic and Rehabilitation Panel compelling ... the counter sales. "It,s been 37 ... classification schema," Whelan said.  "While the old classification ...
(Date:5/21/2013)... 2013  Janssen R&D Ireland (Janssen) today announced ... Phase 3 PROMISE study demonstrating that use of ... sustained virologic response 12 weeks after the end ... genotype 1 chronic hepatitis C adult patients with ... fibrosis, when administered once daily with pegylated interferon ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... Novocure, a commercial stage private oncology company, announced ... supply agreement with ITT Electronic Systems, a subsidiary ... (NYSE: ITT). ITT Electronic Systems supplies Novocure with ... disposable electrodes for the NovoTTF-100A System, an FDA ...
... American Pacific Corporation (NASDAQ: APFC ... its Fiscal 2011 third quarter financial results on Thursday, August ... and Chief Executive Officer and Dana Kelley, Vice President, Chief ... at 1:30 p.m. Pacific Time. Callers may listen ...
Cached Medicine Technology:Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 2Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 3American Pacific to Release Financial Results and Hold Fiscal 2011 Third Quarter Investor Teleconference 2
(Date:5/21/2013)... ContinuCare Home Health, Inc. recently received a ... Disability Services. After completing a four-day review of patient ... Health was found to have no deficiencies to be ... Department of Aging and Disability Services’ mission to provide ... and opportunities that are easily accessed in local ...
(Date:5/21/2013)... 21, 2013 HealthSmart continues to grow ... presence has required the hiring of new talent in ... pleased to announce that Dawn Powell has joined the ... the Director of Account Management in the Central Region ... Irving, Texas. With extensive client management, employee benefits, and ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve the ... Creative Corridor region, is releasing results for its 2013 ... Thursday, May 23rd at 10:30 a.m. The survey ... , The survey is a critical component to the ... nurture and retain people of diverse backgrounds, cultures and ...
Breaking Medicine News(10 mins):Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2
... Tips on What to Do Now as States Struggle,with ... Red Cross,chapters throughout the Midwest are keeping pace with ... landscape, despite several,chapter offices being closed due to the ... from home or using partnerships with,local government or community ...
... 11 AIDS Healthcare,Foundation (AHF) today blasted former ... for his stubbornness and,recent failure to apologize for ... in which he called for people living with,HIV/AIDS ... the time, Huckabee,told Associated Press in response to ...
... Sell Out Consumers with Unaffordable Mandate, SANTA MONICA, ... as much as 14% have led a state panel,to ... health plans. The vote,came less than a month before ... or pay penalties that increase monthly, and as,California politicians ...
... Calls on Every Candidate from Every Party to ... WASHINGTON, Dec. 11 AIDS Action released a,statement ... rewrite,his HIV/AIDS platform to ensure that the policies ... and end stigma against people,living with HIV. "Governor ...
... new study in Nature, Brandeis University Howard Hughes Medical ... curtain on the secret lives of enzymes, the ubiquitous ... a slew of sophisticated technologies to capture a key ... able to show that these proteins are not the ...
... bortezomib (Velcade) and two other drugs is showing a ... multiple myeloma, a team headed by Dana-Farber Cancer Institute ... Society of Hematology. , The three-pronged regimen of Velcade, ... has achieved an overall response rate of 98 ...
Cached Medicine News:Health News:Darkness and Cold Prevail in the Midwest 2Health News:Darkness and Cold Prevail in the Midwest 3Health News:Darkness and Cold Prevail in the Midwest 4Health News:Huckabee's Defense of Earlier, Alarmist AIDS Stance Shows Unsuitability for Presidency, Says AHF 2Health News:Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed 2Health News:AIDS Action Calls on Huckabee to Follow HIV/AIDS Science 2Health News:Caught in the act: The dynamic dance of enzymes 2Health News:3-drug combination 'extremely promising' as first-line therapy for multiple myeloma 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: